Inventiva Launches New ATM Program to Raise $100 Million

October 14, 2025 - Inventiva, a clinical-stage biopharmaceutical firm, has announced a new At-The-Market (ATM) program, allowing it to raise up to $100 million in gross sales. This decision follows the filing of a shelf registration statement on Form F-3 with the SEC. The plan involves issuing American Depositary Shares (ADS) without shareholders' preferential rights, managing a potential 30% dilution over a 12-month period.

The funds will support Inventiva's ongoing research, particularly for the development of lanifibranor, its primary pipeline product. Piper Sandler & Co. will facilitate the sales, targeting select investors engaged in sectors relevant to pharmacology and biotechnology. The company aims to update stakeholders about the program's progress through its quarterly reports.

While the ADSs will trade on Nasdaq, the company stresses that these securities are not yet available for sale pending regulatory approvals. This move signals Inventiva's strategic focus on financing research initiatives crucial to its market growth objectives.